董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kimble L. Jenkins | 男 | Director,Chairman | 54 | 48.51万 | 未持股 | 2016-06-30 |
| Pascal E. R. Girin | 男 | Director | 56 | 3.03万 | 未持股 | 2016-06-30 |
| Philip A. Pizzo | 男 | Director | 71 | 3.33万 | 未持股 | 2016-06-30 |
| Timothy T. Richards | 男 | Director | 58 | 3.38万 | 未持股 | 2016-06-30 |
| Andrew K. Rooke | 男 | Director | 59 | 2.78万 | 未持股 | 2016-06-30 |
| Francis P. Grillo | 男 | Director,Chief Executive Officer and President | 54 | 54.69万 | 未持股 | 2016-06-30 |
| Maria Sainz | 女 | Director | 50 | 3.08万 | 未持股 | 2016-06-30 |
| John N. Spencer, Jr. | 男 | Director | 75 | 3.88万 | 未持股 | 2016-06-30 |
| Charles E. Koob | 男 | Director | 71 | 3.78万 | 未持股 | 2016-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Francis P. Grillo | 男 | Director,Chief Executive Officer and President | 54 | 54.69万 | 未持股 | 2016-06-30 |
| Peter G. Piferi | 男 | Chief Operating Officer | 56 | 未披露 | 未持股 | 2016-06-30 |
| Robert C. Korn | 男 | Vice President, Sales | 51 | 37.93万 | 未持股 | 2016-06-30 |
| Wendelin C. Maners | 女 | Vice President, Marketing | 53 | 未披露 | 未持股 | 2016-06-30 |
| Harold A. Hurwitz | 男 | Chief Financial Officer and Corporate Secretary | 64 | 49.79万 | 未持股 | 2016-06-30 |
董事简历
中英对照 | 中文 | 英文- Kimble L. Jenkins
-
Kimble L. Jenkins，她于2002年9月加入我们董事会。他目前担任我们董事长。从2003年1月至2014年10月，他担任我们总裁。从2004年9月到2014年12月，他担任我们首席执行官。他以兼职的形式担任这两个职位直到2008年5月，他开始担任全职总裁和首席执行官。2014年10月以来，他也担任Theraplex Company LLC（私人持有的皮肤护理产品的公司）的总裁。2008年5月之前，他曾是投资银行Morgan Keegan & Company, Inc.的董事总经理，他在1998年创办公司的私人股权部。
Kimble L. Jenkins joined our Board in September 2002. Mr. Jenkins, who currently serves as the Chairman of our Board, previously served as our President from January 2003 to October 2014 and as our Chief Executive Officer from September 2004 through December 2014. Mr. Jenkins served in those two positions on a part-time basis until May 2008 at which time he began serving as President and Chief Executive Officer on a full-time basis. Since October 2014 Mr. Jenkins has also served as the President of Theraplex Company LLC, a privately held skin care products company. Prior to May 2008 Mr. Jenkins was a Managing Director with the investment bank Morgan Keegan & Company, Inc., where he founded that firm’s Private Equity Group in 1998. - Kimble L. Jenkins，她于2002年9月加入我们董事会。他目前担任我们董事长。从2003年1月至2014年10月，他担任我们总裁。从2004年9月到2014年12月，他担任我们首席执行官。他以兼职的形式担任这两个职位直到2008年5月，他开始担任全职总裁和首席执行官。2014年10月以来，他也担任Theraplex Company LLC（私人持有的皮肤护理产品的公司）的总裁。2008年5月之前，他曾是投资银行Morgan Keegan & Company, Inc.的董事总经理，他在1998年创办公司的私人股权部。
- Kimble L. Jenkins joined our Board in September 2002. Mr. Jenkins, who currently serves as the Chairman of our Board, previously served as our President from January 2003 to October 2014 and as our Chief Executive Officer from September 2004 through December 2014. Mr. Jenkins served in those two positions on a part-time basis until May 2008 at which time he began serving as President and Chief Executive Officer on a full-time basis. Since October 2014 Mr. Jenkins has also served as the President of Theraplex Company LLC, a privately held skin care products company. Prior to May 2008 Mr. Jenkins was a Managing Director with the investment bank Morgan Keegan & Company, Inc., where he founded that firm’s Private Equity Group in 1998.
- Pascal E. R. Girin
-
Pascal E. R. Girin，2014年9月进入Mri Interventions, Inc.董事会。他有着超过20年的医疗技术领域管理和执行经验。他最近于2012年11月至2015年10月间担任Wright Medical Technology, Inc.的执行副总裁兼首席运营官，期间公司成功与Tornier N.V。合并成立Wright Medical Group N.V.。在加入Wright Medical之前，他于2011年2月至2012年6月间担任Keystone Dental Inc.的总裁兼首席执行官，期间公司成功与Southern Implants Inc.合并。2010年10月至2011年2月，他担任了Keystone Dental Inc.的执行副总裁兼首席运营官；2010年7月至9月间担任ev3 Inc.的首席运营官，此前该公司被 Covidien Group S.a.r.l。的全资子公司收购。此前，他于2010年1月至7月间担任ev3 Inc.的执行副总裁兼首席运营官，2008年7月至2010年1月间担任ev3 Neurovascular Inc.的全球神经血管与国际执行副总裁，2005年7月至2008年7月间担任ev3 International的高级副总裁兼国际总裁，2003年9月至2005年7月间担任ev3 Inc.的欧洲地区总经理。1998年9月至2003年8月，他担任了BioScience Europe Baxter Healthcare Corporation的多个职位，最近担任副总裁。他曾就读于the French Ecole des Mines的工程学专业。2010年11月至2012年11月2日，他担任了Tornier N.V。（上市全球医疗器械公司）的董事，兼任其提名、企业治理和合规委员会成员。
Pascal E. R. Girin joined our Board in September 2014. Mr. Girin possesses over two decades of management and executive experience in the field of medical technology. Mr. Girin most recently served as Executive Vice President and Chief Operating Officer of Wright Medical Technology, Inc. from November 2012 until October 2015 at which time the company successfully merged with Tornier N.V. and formed Wright Medical Group N.V. Prior to joining Wright Medical, Mr. Girin served as President and Chief Executive Officer of Keystone Dental Inc. from February 2011 to June 2012 at which time the company successfully merged with Southern Implants Inc. From October 2010 to February 2011 Mr. Girin served as Executive Vice President and Chief Operating Officer of Keystone Dental Inc. From July 2010 to September 2010 Mr. Girin served as Chief Operating Officer of ev3 Inc. following its acquisition by a wholly owned subsidiary of Covidien Group S.a.r.l. Prior to that time, Mr. Girin served as Executive Vice President and Chief Operating Officer of ev3 Inc. from January 2010 to July 2010 as Executive Vice President and President, Worldwide Neurovascular and International of ev3 Neurovascular Inc. from July 2008 to January 2010 as Senior Vice President and President, International of ev3 International from July 2005 to July 2008 and as General Manager, Europe of ev3 Inc. from September 2003 to July 2005. From September 1998 to August 2003 Mr. Girin served in various capacities at BioScience Europe Baxter Healthcare Corporation, most recently as Vice President. Mr. Girin received an engineering education at the French Ecole des Mines. From November 2010 until November 2 2012 Mr. Girin had served as a director of Tornier N.V., a publicly traded global medical device company, as well as a member of its Nominating, Corporate Governance and Compliance Committee. - Pascal E. R. Girin，2014年9月进入Mri Interventions, Inc.董事会。他有着超过20年的医疗技术领域管理和执行经验。他最近于2012年11月至2015年10月间担任Wright Medical Technology, Inc.的执行副总裁兼首席运营官，期间公司成功与Tornier N.V。合并成立Wright Medical Group N.V.。在加入Wright Medical之前，他于2011年2月至2012年6月间担任Keystone Dental Inc.的总裁兼首席执行官，期间公司成功与Southern Implants Inc.合并。2010年10月至2011年2月，他担任了Keystone Dental Inc.的执行副总裁兼首席运营官；2010年7月至9月间担任ev3 Inc.的首席运营官，此前该公司被 Covidien Group S.a.r.l。的全资子公司收购。此前，他于2010年1月至7月间担任ev3 Inc.的执行副总裁兼首席运营官，2008年7月至2010年1月间担任ev3 Neurovascular Inc.的全球神经血管与国际执行副总裁，2005年7月至2008年7月间担任ev3 International的高级副总裁兼国际总裁，2003年9月至2005年7月间担任ev3 Inc.的欧洲地区总经理。1998年9月至2003年8月，他担任了BioScience Europe Baxter Healthcare Corporation的多个职位，最近担任副总裁。他曾就读于the French Ecole des Mines的工程学专业。2010年11月至2012年11月2日，他担任了Tornier N.V。（上市全球医疗器械公司）的董事，兼任其提名、企业治理和合规委员会成员。
- Pascal E. R. Girin joined our Board in September 2014. Mr. Girin possesses over two decades of management and executive experience in the field of medical technology. Mr. Girin most recently served as Executive Vice President and Chief Operating Officer of Wright Medical Technology, Inc. from November 2012 until October 2015 at which time the company successfully merged with Tornier N.V. and formed Wright Medical Group N.V. Prior to joining Wright Medical, Mr. Girin served as President and Chief Executive Officer of Keystone Dental Inc. from February 2011 to June 2012 at which time the company successfully merged with Southern Implants Inc. From October 2010 to February 2011 Mr. Girin served as Executive Vice President and Chief Operating Officer of Keystone Dental Inc. From July 2010 to September 2010 Mr. Girin served as Chief Operating Officer of ev3 Inc. following its acquisition by a wholly owned subsidiary of Covidien Group S.a.r.l. Prior to that time, Mr. Girin served as Executive Vice President and Chief Operating Officer of ev3 Inc. from January 2010 to July 2010 as Executive Vice President and President, Worldwide Neurovascular and International of ev3 Neurovascular Inc. from July 2008 to January 2010 as Senior Vice President and President, International of ev3 International from July 2005 to July 2008 and as General Manager, Europe of ev3 Inc. from September 2003 to July 2005. From September 1998 to August 2003 Mr. Girin served in various capacities at BioScience Europe Baxter Healthcare Corporation, most recently as Vice President. Mr. Girin received an engineering education at the French Ecole des Mines. From November 2010 until November 2 2012 Mr. Girin had served as a director of Tornier N.V., a publicly traded global medical device company, as well as a member of its Nominating, Corporate Governance and Compliance Committee.
- Philip A. Pizzo
-
Philip A. Pizzo，他于2013年4月加入我们的董事会。他曾担任the Stanford School of Medicine的院长（2011年4月至2012年12月1日），在那里他也曾担任卡尔和伊丽莎白·瑙曼儿科和微生物学和免疫学教授。他的杰出的医学事业大都致力于诊断、管理、预防、治疗儿童癌症和感染性并发症，涉及患有癌症和艾滋病的免疫系统受损的儿童。他也是一个通过学术医学、支持项目和政策来改善美国科学、教育和医疗未来的领导人。加入Stanford之前，他曾担任Children’s Hospital（位于波士顿）的主治医师，以及Harvard Medical School的儿科系的主席（1996年至2001年）。他是500多篇科学论文、16书籍和专著的作者。他目前任职于Global Blood Therapeutics, Inc.（上市临床分期生物制药公司）、the University of Rochester（私人大学）、Koc University（私立大学，位于土耳其伊斯坦布尔）的董事会、管理机构。
Philip A. Pizzo M.D. has served as a member of the company's Board of Directors since September 2015. Dr. Pizzo currently serves as the David and Susan Heckerman Professor of Pediatrics and of Microbiology and Immunology at Stanford School of Medicine and is a founding director of the Stanford Distinguished Careers Institute. Since 2013 he has served on the board of directors of MRI Interventions, Inc., a publicly-traded medical device company. He previously served as Dean of the Stanford School of Medicine from 2001 to 2012 where he was also the Carl and Elizabeth Naumann Professor of Pediatrics and of Microbiology and Immunology. Before joining Stanford, he was the physician-in-chief of Children’s Hospital in Boston and chair of the Department of Pediatrics at Harvard Medical School from 1996 to 2001. Prior to that, Dr. Pizzo was at the National Cancer Institute, eventually serving as chief of pediatrics and acting scientific director in the Division of Clinical Sciences. Dr. Pizzo is the author of more than 630 scientific articles and 16 books and monographs, has received numerous awards and honors, is a member of the Institute of Medicine, and serves on several international boards. Dr. Pizzo holds a B.A. from Fordham University and an M.D. from the University of Rochester, School of Medicine. - Philip A. Pizzo，他于2013年4月加入我们的董事会。他曾担任the Stanford School of Medicine的院长（2011年4月至2012年12月1日），在那里他也曾担任卡尔和伊丽莎白·瑙曼儿科和微生物学和免疫学教授。他的杰出的医学事业大都致力于诊断、管理、预防、治疗儿童癌症和感染性并发症，涉及患有癌症和艾滋病的免疫系统受损的儿童。他也是一个通过学术医学、支持项目和政策来改善美国科学、教育和医疗未来的领导人。加入Stanford之前，他曾担任Children’s Hospital（位于波士顿）的主治医师，以及Harvard Medical School的儿科系的主席（1996年至2001年）。他是500多篇科学论文、16书籍和专著的作者。他目前任职于Global Blood Therapeutics, Inc.（上市临床分期生物制药公司）、the University of Rochester（私人大学）、Koc University（私立大学，位于土耳其伊斯坦布尔）的董事会、管理机构。
- Philip A. Pizzo M.D. has served as a member of the company's Board of Directors since September 2015. Dr. Pizzo currently serves as the David and Susan Heckerman Professor of Pediatrics and of Microbiology and Immunology at Stanford School of Medicine and is a founding director of the Stanford Distinguished Careers Institute. Since 2013 he has served on the board of directors of MRI Interventions, Inc., a publicly-traded medical device company. He previously served as Dean of the Stanford School of Medicine from 2001 to 2012 where he was also the Carl and Elizabeth Naumann Professor of Pediatrics and of Microbiology and Immunology. Before joining Stanford, he was the physician-in-chief of Children’s Hospital in Boston and chair of the Department of Pediatrics at Harvard Medical School from 1996 to 2001. Prior to that, Dr. Pizzo was at the National Cancer Institute, eventually serving as chief of pediatrics and acting scientific director in the Division of Clinical Sciences. Dr. Pizzo is the author of more than 630 scientific articles and 16 books and monographs, has received numerous awards and honors, is a member of the Institute of Medicine, and serves on several international boards. Dr. Pizzo holds a B.A. from Fordham University and an M.D. from the University of Rochester, School of Medicine.
- Timothy T. Richards
-
Timothy T. Richards，他于2014年3月加入我们董事会。2012年10月以来，他曾任职Seventh Sense BioSystems, Inc.（风险投资支持初创公司，专注于医疗点诊断测试），在那里他曾招募建立和开发公司的业务发展和商业组织。目前，他担任Seventh Sense BioSystems的首席运营官。加入Seventh Sense BioSystems之前，他曾担任Facet Technologies, LLC（大型诊断公司的私人供应商）的总裁（从2011年10月到2012年8月），在那里他曾领导公司的制造和供应链平台。2008年11月至2010年5月，他曾担任Covidien机构的执行职务，最初担任病人护理和安全产品业务单元的美国总裁，随后担任VNUS Medical Technologies（2009年公司被Covidien收购）的总裁。从2003年10月到2008年10月，他曾担任B. Braun Medical Inc.（输液治疗和疼痛管理的领导者）的高级副总裁、首席营销官和执行董事会成员。加入B. Braun Medical之前，他曾担任Becton Dickinson and Company的多种美国和亚洲领导职务，并不断被提拔。
Timothy T. Richards joined our Board in March 2014. Since October 2012 Mr. Richards has worked for Seventh Sense BioSystems, Inc., a venture capital-backed start-up with a focus on point-of-care diagnostic testing, where he was recruited to build and develop the company’s business development and commercial organization. Currently, Mr. Richards serves as Seventh Sense BioSystems’ Chief Operating Officer. Prior to joining Seventh Sense BioSystems, from October 2011 through August 2012 Mr. Richards served as President of Facet Technologies, LLC, a privately-held supplier to major diagnostic companies, where he led the company’s manufacturing and supply chain platform. From November 2008 until May 2010 Mr. Richards held executive-level positions within the Covidien organization, first as U.S. President of the Patient Care & Safety Products business unit, and subsequently as President of VNUS Medical Technologies following its acquisition by Covidien in 2009. From October 2003 through October 2008 Mr. Richards served as Senior Vice President, Chief Marketing Officer and a member of the Executive Board of B. Braun Medical Inc., a leader in infusion therapy and pain management. Before joining B. Braun Medical, he held a number of progressive leadership positions throughout the U.S. and Asia with Becton Dickinson and Company. - Timothy T. Richards，他于2014年3月加入我们董事会。2012年10月以来，他曾任职Seventh Sense BioSystems, Inc.（风险投资支持初创公司，专注于医疗点诊断测试），在那里他曾招募建立和开发公司的业务发展和商业组织。目前，他担任Seventh Sense BioSystems的首席运营官。加入Seventh Sense BioSystems之前，他曾担任Facet Technologies, LLC（大型诊断公司的私人供应商）的总裁（从2011年10月到2012年8月），在那里他曾领导公司的制造和供应链平台。2008年11月至2010年5月，他曾担任Covidien机构的执行职务，最初担任病人护理和安全产品业务单元的美国总裁，随后担任VNUS Medical Technologies（2009年公司被Covidien收购）的总裁。从2003年10月到2008年10月，他曾担任B. Braun Medical Inc.（输液治疗和疼痛管理的领导者）的高级副总裁、首席营销官和执行董事会成员。加入B. Braun Medical之前，他曾担任Becton Dickinson and Company的多种美国和亚洲领导职务，并不断被提拔。
- Timothy T. Richards joined our Board in March 2014. Since October 2012 Mr. Richards has worked for Seventh Sense BioSystems, Inc., a venture capital-backed start-up with a focus on point-of-care diagnostic testing, where he was recruited to build and develop the company’s business development and commercial organization. Currently, Mr. Richards serves as Seventh Sense BioSystems’ Chief Operating Officer. Prior to joining Seventh Sense BioSystems, from October 2011 through August 2012 Mr. Richards served as President of Facet Technologies, LLC, a privately-held supplier to major diagnostic companies, where he led the company’s manufacturing and supply chain platform. From November 2008 until May 2010 Mr. Richards held executive-level positions within the Covidien organization, first as U.S. President of the Patient Care & Safety Products business unit, and subsequently as President of VNUS Medical Technologies following its acquisition by Covidien in 2009. From October 2003 through October 2008 Mr. Richards served as Senior Vice President, Chief Marketing Officer and a member of the Executive Board of B. Braun Medical Inc., a leader in infusion therapy and pain management. Before joining B. Braun Medical, he held a number of progressive leadership positions throughout the U.S. and Asia with Becton Dickinson and Company.
- Andrew K. Rooke
-
Andrew K. Rooke，2011年7月加入我们董事会。Rooke先生持有并管理专门从事投资管理公众持有的证券和众多的信托投资的监督私人信托公司 Rooke Fiduciary Management。Rooke先生也是私人基金会Withington Foundation总裁和董事。过去几年，他收购，管理并出售了多个私人公司和商业房地产资产。
Andrew K. Rooke joined our Board in July 2011. Mr. Rooke owns and manages Rooke Fiduciary Management, a private trust company, which specializes in the investment management of publicly held securities and the oversight of a multitude of trust investments. Mr. Rooke is also President and a director of Withington Foundation, a private foundation. Over the years, he has acquired, managed and sold a number of private companies as well as commercial real estate properties. - Andrew K. Rooke，2011年7月加入我们董事会。Rooke先生持有并管理专门从事投资管理公众持有的证券和众多的信托投资的监督私人信托公司 Rooke Fiduciary Management。Rooke先生也是私人基金会Withington Foundation总裁和董事。过去几年，他收购，管理并出售了多个私人公司和商业房地产资产。
- Andrew K. Rooke joined our Board in July 2011. Mr. Rooke owns and manages Rooke Fiduciary Management, a private trust company, which specializes in the investment management of publicly held securities and the oversight of a multitude of trust investments. Mr. Rooke is also President and a director of Withington Foundation, a private foundation. Over the years, he has acquired, managed and sold a number of private companies as well as commercial real estate properties.
- Francis P. Grillo
-
Francis P. Grillo，他于2014年10月加入我们，并担任总裁。他于2015年1月1日成为我们首席执行官，并于2015年4月成为我们董事会成员。加入我们公司之前，他曾担任Intuitive Surgical, Inc.（上市医疗技术公司）的营销和新业务发展副总裁（2008年8月以来）。加入Intuitive Surgical之前，他曾任职Kyphon Inc.，最近担任营销和业务发展副总裁（从2006年2月到2008年6月）。2007年11月被Medtronic, Inc.收购之前，Kyphon曾是上市医疗技术公司。任职Kyphon之前，他担任Boston Scientific Corporation的各种职位，最近担任女性健康、泌尿外科、妇科营销副总裁（从1996年9月到2006年1月）。他目前担任Embolx, Inc.（上市医疗设备公司）的董事会职位。
Francis P. Grillo joined us in October 2014 as President. Mr. Grillo also became our Chief Executive Officer effective January 1 2015 and became a member of our Board in April 2015. Prior to joining our company, Mr. Grillo served as Vice President, Marketing and New Business Development of Intuitive Surgical, Inc., a publicly-traded medical technology company, since August 2008. Before joining Intuitive Surgical, Mr. Grillo worked for Kyphon Inc. from February 2006 to June 2008 most recently as Vice President, Marketing and Business Development. Kyphon was a publicly-traded medical technology company prior to its acquisition by Medtronic, Inc. in November 2007. Prior to Kyphon, from September 1996 to January 2006 Mr. Grillo held various positions at Boston Scientific Corporation, most recently as Vice President, Marketing, Women’s Health, Urology/Gynecology Division. Mr. Grillo presently serves on the board of directors of Embolx, Inc., a privately held medical device company. - Francis P. Grillo，他于2014年10月加入我们，并担任总裁。他于2015年1月1日成为我们首席执行官，并于2015年4月成为我们董事会成员。加入我们公司之前，他曾担任Intuitive Surgical, Inc.（上市医疗技术公司）的营销和新业务发展副总裁（2008年8月以来）。加入Intuitive Surgical之前，他曾任职Kyphon Inc.，最近担任营销和业务发展副总裁（从2006年2月到2008年6月）。2007年11月被Medtronic, Inc.收购之前，Kyphon曾是上市医疗技术公司。任职Kyphon之前，他担任Boston Scientific Corporation的各种职位，最近担任女性健康、泌尿外科、妇科营销副总裁（从1996年9月到2006年1月）。他目前担任Embolx, Inc.（上市医疗设备公司）的董事会职位。
- Francis P. Grillo joined us in October 2014 as President. Mr. Grillo also became our Chief Executive Officer effective January 1 2015 and became a member of our Board in April 2015. Prior to joining our company, Mr. Grillo served as Vice President, Marketing and New Business Development of Intuitive Surgical, Inc., a publicly-traded medical technology company, since August 2008. Before joining Intuitive Surgical, Mr. Grillo worked for Kyphon Inc. from February 2006 to June 2008 most recently as Vice President, Marketing and Business Development. Kyphon was a publicly-traded medical technology company prior to its acquisition by Medtronic, Inc. in November 2007. Prior to Kyphon, from September 1996 to January 2006 Mr. Grillo held various positions at Boston Scientific Corporation, most recently as Vice President, Marketing, Women’s Health, Urology/Gynecology Division. Mr. Grillo presently serves on the board of directors of Embolx, Inc., a privately held medical device company.
- Maria Sainz
-
Maria Sainz，Sainz女士自2018年4月起担任公司董事。Sainz女士于2012年5月至2017年7月担任Cardiokinetix Inc.（一家开发经导管植入物的私人公司）的总裁，首席执行官兼董事。Sainz女士于2011年10月至2012年5月被史赛克公司收购，担任神经血管医疗技术公司Concentric Medical，Inc.的总裁兼首席执行官。Sainz女士曾担任Guidant Corporation/Boston Scientific心脏外科部门的总裁，在担任该职位之前，曾担任多个职责递增的销售与市场营销管理职位。Sainz女士目前在Orthofix International NV，Halyard Health，Inc.和MRI Interventions的董事会任职。Sainz女士拥有西班牙马德里the University Complutense的语言硕士学位和美国国际管理研究生院的国际管理硕士学位。
Maria Sainz, Ms. Sainz has served as a director of the Company since April 2018. Ms. Sainz served as the President, Chief Executive Officer, and Director of CardioKinetix Inc., a private company that developed transcatheter implants from May 2012 to July 2017. Ms. Sainz was the President and Chief Executive Officer of Concentric Medical, Inc., a neurovascular medical technology company, through its acquisition by Stryker Corporation in October 2011 until May 2012. Ms. Sainz served as the President of the Cardiac Surgery division of Guidant Corporation/Boston Scientific and prior to that position in several sales and marketing management positions of increasing responsibility. Ms. Sainz currently serves on the board of directors of Orthofix International NV, Halyard Health, Inc. and MRI Interventions. Ms. Sainz holds a M.A. in Languages from the University Complutense in Madrid, Spain and a Master's Degree in International Management from the American Graduate School of International Management. - Maria Sainz，Sainz女士自2018年4月起担任公司董事。Sainz女士于2012年5月至2017年7月担任Cardiokinetix Inc.（一家开发经导管植入物的私人公司）的总裁，首席执行官兼董事。Sainz女士于2011年10月至2012年5月被史赛克公司收购，担任神经血管医疗技术公司Concentric Medical，Inc.的总裁兼首席执行官。Sainz女士曾担任Guidant Corporation/Boston Scientific心脏外科部门的总裁，在担任该职位之前，曾担任多个职责递增的销售与市场营销管理职位。Sainz女士目前在Orthofix International NV，Halyard Health，Inc.和MRI Interventions的董事会任职。Sainz女士拥有西班牙马德里the University Complutense的语言硕士学位和美国国际管理研究生院的国际管理硕士学位。
- Maria Sainz, Ms. Sainz has served as a director of the Company since April 2018. Ms. Sainz served as the President, Chief Executive Officer, and Director of CardioKinetix Inc., a private company that developed transcatheter implants from May 2012 to July 2017. Ms. Sainz was the President and Chief Executive Officer of Concentric Medical, Inc., a neurovascular medical technology company, through its acquisition by Stryker Corporation in October 2011 until May 2012. Ms. Sainz served as the President of the Cardiac Surgery division of Guidant Corporation/Boston Scientific and prior to that position in several sales and marketing management positions of increasing responsibility. Ms. Sainz currently serves on the board of directors of Orthofix International NV, Halyard Health, Inc. and MRI Interventions. Ms. Sainz holds a M.A. in Languages from the University Complutense in Madrid, Spain and a Master's Degree in International Management from the American Graduate School of International Management.
- John N. Spencer, Jr.
-
John N. Spencer, Jr.，从2013年11月到2014年2月，他曾担任Applied Genetic Technologies Corporation（公开上市的生物技术公司，在美国证券交易委员会登记）的临时首席财务官。他是注册会计师，也曾担任安永会计师事务所（Ernst & Young）的合伙人，在那里他曾任职38年以上（2000年退休之前）。他任职于MRI Interventions公司（医疗设备公司）和Geovax Labs公司（一个生物科技公司，在那里他是提名和治理委员会主席）的董事会，并担任其审计委员会主席。他也曾担任Firstwave Technologies公司（客户关系管理产品的供应商）的董事、审计委员会主席（从2003年11月到2009年4月）。他担任多家公司的顾问，主要涉及财务会计和报告问题。他拥有Syracuse University的学士学位，以及Babson College的工商管理硕士学位。他也完成了哈佛商学院（Harvard Business School）的进阶管理课程（Advanced Management Program）。
John N. Spencer, Jr. joined the Board of Directors in September 2006. Mr. Spencer is a certified public accountant and was a partner of Ernst & Young LLP where he spent more than 38 years until he retired in 2000. Mr. Spencer holds a Bachelor of Science degree from Syrace University, and MBA from Babson College. He also attended the Harvard Biness School Advanced Management Program. - John N. Spencer, Jr.，从2013年11月到2014年2月，他曾担任Applied Genetic Technologies Corporation（公开上市的生物技术公司，在美国证券交易委员会登记）的临时首席财务官。他是注册会计师，也曾担任安永会计师事务所（Ernst & Young）的合伙人，在那里他曾任职38年以上（2000年退休之前）。他任职于MRI Interventions公司（医疗设备公司）和Geovax Labs公司（一个生物科技公司，在那里他是提名和治理委员会主席）的董事会，并担任其审计委员会主席。他也曾担任Firstwave Technologies公司（客户关系管理产品的供应商）的董事、审计委员会主席（从2003年11月到2009年4月）。他担任多家公司的顾问，主要涉及财务会计和报告问题。他拥有Syracuse University的学士学位，以及Babson College的工商管理硕士学位。他也完成了哈佛商学院（Harvard Business School）的进阶管理课程（Advanced Management Program）。
- John N. Spencer, Jr. joined the Board of Directors in September 2006. Mr. Spencer is a certified public accountant and was a partner of Ernst & Young LLP where he spent more than 38 years until he retired in 2000. Mr. Spencer holds a Bachelor of Science degree from Syrace University, and MBA from Babson College. He also attended the Harvard Biness School Advanced Management Program.
- Charles E. Koob
-
Charles E. Koob，它目前是我公司董事。他于2008年2月和3月分别成为Alynx和MiMedx Group, Inc.的董事。他在2007年4月首次当选为MiMedx, Inc.董事。他于1970年加入Simpson Thacher & Bartlett, LLP律师事务所，在1997年成为合伙人并于2007年1月1日从事务所退休。在事务所工作期间，他共同领导诉讼部并是执行委员会成员。他专长为竞争、贸易规则和反垄断。在他37年的律师生涯中，他在the Federal Trade Commission, the Antitrust Division of the Department of Justice以及无数州立和国外公平竞争委员会前为客户辩护过。他代表过Virgin Atlantic Airways, Archer Daniels Midland， 和Kohlberg Kravis Roberts and Co.他于1966年从Rockhurst College获得学士学位并于1969年从斯坦福法学院（Stanford Law School）获得法学博士学位。他曾担任Stanford Hospital and Clinics、私有药物发展公司和上市医疗设备公司MRI Interventions董事。
Charles E. Koob serves on the Company's Board of Directors. He became a Director of Alynx in February 2008 and of MiMedx Group, Inc. in March 2008. He was first elected as a Director of MiMedx, Inc. in April 2007. Mr. Koob joined the law firm of Simpson Thacher & Bartlett, LLP in 1970 and became a partner in 1977. He retired from that firm on January 1 2007. While at that firm, Mr. Koob was the co-head of the Litigation Department and served on the firm’s Executive Committee. Mr. Koob specialized in competition, trade regulation and antitrust issues. Throughout his 37-year tenure, he represented clients before the Federal Trade Commission, the Antitrust Division of the Department of Justice, and numerous state and foreign competition authorities. His résumé includes the representation of Virgin Atlantic Airways, Archer Daniels Midland, and Kohlberg Kravis Roberts and Co. He received his B.A. from Rockhurst College in 1966 and his J.D. from Stanford Law School in 1969. Mr. Koob serves on the board of Stanford Hospital and Clinics. He also serves on the board of a private drug development company and MRI Interventions OTCBB: MRIC, a publicly traded medical device company. - Charles E. Koob，它目前是我公司董事。他于2008年2月和3月分别成为Alynx和MiMedx Group, Inc.的董事。他在2007年4月首次当选为MiMedx, Inc.董事。他于1970年加入Simpson Thacher & Bartlett, LLP律师事务所，在1997年成为合伙人并于2007年1月1日从事务所退休。在事务所工作期间，他共同领导诉讼部并是执行委员会成员。他专长为竞争、贸易规则和反垄断。在他37年的律师生涯中，他在the Federal Trade Commission, the Antitrust Division of the Department of Justice以及无数州立和国外公平竞争委员会前为客户辩护过。他代表过Virgin Atlantic Airways, Archer Daniels Midland， 和Kohlberg Kravis Roberts and Co.他于1966年从Rockhurst College获得学士学位并于1969年从斯坦福法学院（Stanford Law School）获得法学博士学位。他曾担任Stanford Hospital and Clinics、私有药物发展公司和上市医疗设备公司MRI Interventions董事。
- Charles E. Koob serves on the Company's Board of Directors. He became a Director of Alynx in February 2008 and of MiMedx Group, Inc. in March 2008. He was first elected as a Director of MiMedx, Inc. in April 2007. Mr. Koob joined the law firm of Simpson Thacher & Bartlett, LLP in 1970 and became a partner in 1977. He retired from that firm on January 1 2007. While at that firm, Mr. Koob was the co-head of the Litigation Department and served on the firm’s Executive Committee. Mr. Koob specialized in competition, trade regulation and antitrust issues. Throughout his 37-year tenure, he represented clients before the Federal Trade Commission, the Antitrust Division of the Department of Justice, and numerous state and foreign competition authorities. His résumé includes the representation of Virgin Atlantic Airways, Archer Daniels Midland, and Kohlberg Kravis Roberts and Co. He received his B.A. from Rockhurst College in 1966 and his J.D. from Stanford Law School in 1969. Mr. Koob serves on the board of Stanford Hospital and Clinics. He also serves on the board of a private drug development company and MRI Interventions OTCBB: MRIC, a publicly traded medical device company.
高管简历
中英对照 | 中文 | 英文- Francis P. Grillo
Francis P. Grillo，他于2014年10月加入我们，并担任总裁。他于2015年1月1日成为我们首席执行官，并于2015年4月成为我们董事会成员。加入我们公司之前，他曾担任Intuitive Surgical, Inc.（上市医疗技术公司）的营销和新业务发展副总裁（2008年8月以来）。加入Intuitive Surgical之前，他曾任职Kyphon Inc.，最近担任营销和业务发展副总裁（从2006年2月到2008年6月）。2007年11月被Medtronic, Inc.收购之前，Kyphon曾是上市医疗技术公司。任职Kyphon之前，他担任Boston Scientific Corporation的各种职位，最近担任女性健康、泌尿外科、妇科营销副总裁（从1996年9月到2006年1月）。他目前担任Embolx, Inc.（上市医疗设备公司）的董事会职位。
Francis P. Grillo joined us in October 2014 as President. Mr. Grillo also became our Chief Executive Officer effective January 1 2015 and became a member of our Board in April 2015. Prior to joining our company, Mr. Grillo served as Vice President, Marketing and New Business Development of Intuitive Surgical, Inc., a publicly-traded medical technology company, since August 2008. Before joining Intuitive Surgical, Mr. Grillo worked for Kyphon Inc. from February 2006 to June 2008 most recently as Vice President, Marketing and Business Development. Kyphon was a publicly-traded medical technology company prior to its acquisition by Medtronic, Inc. in November 2007. Prior to Kyphon, from September 1996 to January 2006 Mr. Grillo held various positions at Boston Scientific Corporation, most recently as Vice President, Marketing, Women’s Health, Urology/Gynecology Division. Mr. Grillo presently serves on the board of directors of Embolx, Inc., a privately held medical device company.- Francis P. Grillo，他于2014年10月加入我们，并担任总裁。他于2015年1月1日成为我们首席执行官，并于2015年4月成为我们董事会成员。加入我们公司之前，他曾担任Intuitive Surgical, Inc.（上市医疗技术公司）的营销和新业务发展副总裁（2008年8月以来）。加入Intuitive Surgical之前，他曾任职Kyphon Inc.，最近担任营销和业务发展副总裁（从2006年2月到2008年6月）。2007年11月被Medtronic, Inc.收购之前，Kyphon曾是上市医疗技术公司。任职Kyphon之前，他担任Boston Scientific Corporation的各种职位，最近担任女性健康、泌尿外科、妇科营销副总裁（从1996年9月到2006年1月）。他目前担任Embolx, Inc.（上市医疗设备公司）的董事会职位。
- Francis P. Grillo joined us in October 2014 as President. Mr. Grillo also became our Chief Executive Officer effective January 1 2015 and became a member of our Board in April 2015. Prior to joining our company, Mr. Grillo served as Vice President, Marketing and New Business Development of Intuitive Surgical, Inc., a publicly-traded medical technology company, since August 2008. Before joining Intuitive Surgical, Mr. Grillo worked for Kyphon Inc. from February 2006 to June 2008 most recently as Vice President, Marketing and Business Development. Kyphon was a publicly-traded medical technology company prior to its acquisition by Medtronic, Inc. in November 2007. Prior to Kyphon, from September 1996 to January 2006 Mr. Grillo held various positions at Boston Scientific Corporation, most recently as Vice President, Marketing, Women’s Health, Urology/Gynecology Division. Mr. Grillo presently serves on the board of directors of Embolx, Inc., a privately held medical device company.
- Peter G. Piferi
Peter G. Piferi，他于2006年12月加入我们，担任首席营运官。从2003年3月到2006年12月，他曾是Edwards Lifesciences Corporation的副总裁，负责血管内技术。此外，他曾担任Kriton Medical Inc、Orbus Medical Technologies Inc的副总裁，以及Cordis Corporation的高级工程董事。
Peter G. Piferi joined us in December 2006 as Chief Operating Officer. From March 2003 to December 2006 Mr. Piferi served as Vice President, Endovascular Technologies for Edwards Lifesciences Corporation. In addition, Mr. Piferi has served as Vice President at Kriton Medical Inc. and Orbus Medical Technologies, Inc., and as Director of Advanced Engineering at Cordis Corporation.- Peter G. Piferi，他于2006年12月加入我们，担任首席营运官。从2003年3月到2006年12月，他曾是Edwards Lifesciences Corporation的副总裁，负责血管内技术。此外，他曾担任Kriton Medical Inc、Orbus Medical Technologies Inc的副总裁，以及Cordis Corporation的高级工程董事。
- Peter G. Piferi joined us in December 2006 as Chief Operating Officer. From March 2003 to December 2006 Mr. Piferi served as Vice President, Endovascular Technologies for Edwards Lifesciences Corporation. In addition, Mr. Piferi has served as Vice President at Kriton Medical Inc. and Orbus Medical Technologies, Inc., and as Director of Advanced Engineering at Cordis Corporation.
- Robert C. Korn
Robert C. Korn，他于2012年11月加入我们并担任我们销售副总裁。他在医疗保健行业拥有超过20年的经验，从事医疗设备销售和营销业务。在他的职务生涯，他在财富500强和创业公司获得发展和实施销售和营销策略的经验。从2005年5月到2012年11月，他担任Medtronic Surgical Technologies（神经外科、耳朵、鼻子和喉咙）和Medtronic, Inc.先进能源业务的、的区域销售主管。担任该职位时，他管理中东的一个销售和临床支持团队，负责每年收入超过3000万美元。在Medtronic时，他拥有业务开发和收购机会的丰富工作经验。2010年他被任命为在the Medtronic Corporate Neuroscience Advisory Team任职。Medtronic之前从2004年4月到2005年4月，他担任Vassol, Inc.（私人公司）的高级副总裁，负责公司的销售和营销职能。Vassol之前，他担任Codman（强生公司，a Johnson & Johnson company）的各种销售领导职务。他也担任the Bayer Corporation的诊断学部门的许多销售和营销职务。
Robert C. Korn joined us in November 2012 and he serves as our Vice President, Sales. Mr. Korn has over 20 years of experience in the health care industry focused in the medical device sales and marketing business. During his career, Mr. Korn gained experience in developing and implementing sales and marketing strategies for both Fortune 500 and startup companies. From May 2005 to November 2012 Mr. Korn served as a Regional Sales Director with Medtronic Surgical Technologies, the neurosurgery, ear, nose and throat ENT and advanced energy business of Medtronic, Inc. In that position, Mr. Korn managed a sales and clinical support team in the Midwest, and he was responsible for revenues in excess of $30 million per year. While at Medtronic, Mr. Korn also worked extensively on business development and acquisition opportunities. In 2010 Mr. Korn was named to the Medtronic Corporate Neuroscience Advisory Team. Prior to joining Medtronic, from April 2004 to April 2005 Mr. Korn served as Senior Vice President for Vassol, Inc., a private company, where he was responsible for the company’s sales and marketing functions. Prior to Vassol, Mr. Korn held various sales leadership positions with Codman, a Johnson & Johnson company, and he also held multiple sales and marketing positions with the Bayer Corporation’s Diagnostics Division.- Robert C. Korn，他于2012年11月加入我们并担任我们销售副总裁。他在医疗保健行业拥有超过20年的经验，从事医疗设备销售和营销业务。在他的职务生涯，他在财富500强和创业公司获得发展和实施销售和营销策略的经验。从2005年5月到2012年11月，他担任Medtronic Surgical Technologies（神经外科、耳朵、鼻子和喉咙）和Medtronic, Inc.先进能源业务的、的区域销售主管。担任该职位时，他管理中东的一个销售和临床支持团队，负责每年收入超过3000万美元。在Medtronic时，他拥有业务开发和收购机会的丰富工作经验。2010年他被任命为在the Medtronic Corporate Neuroscience Advisory Team任职。Medtronic之前从2004年4月到2005年4月，他担任Vassol, Inc.（私人公司）的高级副总裁，负责公司的销售和营销职能。Vassol之前，他担任Codman（强生公司，a Johnson & Johnson company）的各种销售领导职务。他也担任the Bayer Corporation的诊断学部门的许多销售和营销职务。
- Robert C. Korn joined us in November 2012 and he serves as our Vice President, Sales. Mr. Korn has over 20 years of experience in the health care industry focused in the medical device sales and marketing business. During his career, Mr. Korn gained experience in developing and implementing sales and marketing strategies for both Fortune 500 and startup companies. From May 2005 to November 2012 Mr. Korn served as a Regional Sales Director with Medtronic Surgical Technologies, the neurosurgery, ear, nose and throat ENT and advanced energy business of Medtronic, Inc. In that position, Mr. Korn managed a sales and clinical support team in the Midwest, and he was responsible for revenues in excess of $30 million per year. While at Medtronic, Mr. Korn also worked extensively on business development and acquisition opportunities. In 2010 Mr. Korn was named to the Medtronic Corporate Neuroscience Advisory Team. Prior to joining Medtronic, from April 2004 to April 2005 Mr. Korn served as Senior Vice President for Vassol, Inc., a private company, where he was responsible for the company’s sales and marketing functions. Prior to Vassol, Mr. Korn held various sales leadership positions with Codman, a Johnson & Johnson company, and he also held multiple sales and marketing positions with the Bayer Corporation’s Diagnostics Division.
- Wendelin C. Maners
Wendelin C. Maners，她于2014年12月加入我们，担任营销副总裁。她拥有20年以上的全球医疗设备经验，专注于市场营销、采购和医疗设备技术的许可。加入MRI Interventions之前，她曾担任CSA Medical Inc.的新兴技术副总裁，在那里她曾管理公司产品的商业营销，领导公司的新兴应用在新的市场和疾病细分中的市场开发，以及开发内部和外部的产品培训计划。任职CSA Medical之前，她曾任职Boston Scientific Corporation14年以上，担任多种职务，最近担任战略和商业开发副总裁。期间，她曾开发和执行神经调节和电生理学市场的收购战略、管理和建立技术和风险资本的业务关系从而创立一个投资选择支持部门的投资组合，也曾担任科学投资的代表董事会成员/观察者，其中包括Cyberonics, Inc.、Northstar Neuroscience, Inc.、Neuropace, Inc.、Intelect Medical, Inc.、IntraPace, Inc.、Quallion LLC和公司。
Wendelin C. Maners joined us in December 2014 as Vice President, Marketing. Ms. Maners has more than two decades of global medical device experience focused on the marketing, acquisition, and licensing of medical device technologies. Prior to joining MRI Interventions, Ms. Maners served as Vice President, Emerging Technologies with CSA Medical Inc., where she managed commercial marketing for the company’s products, led market development efforts for the company’s emerging applications in new market and disease segments and developed internal and external product training programs. Prior to her time with CSA Medical, Ms. Maners served for over 14 years in various roles at Boston Scientific Corporation, most recently as Vice President, Strategy and Business Development. During that time, she developed and executed acquisition strategies in the Neuromodulation and Electrophysiology markets, managed and built technology and venture capital business relationships to assemble a portfolio of investment options for supported divisions and served as a delegate Board member/observer for Boston Scientific investments, including Cyberonics, Inc., Northstar Neuroscience, Inc., Neuropace, Inc., Intelect Medical, Inc., IntraPace, Inc., Quallion LLC and the Company.- Wendelin C. Maners，她于2014年12月加入我们，担任营销副总裁。她拥有20年以上的全球医疗设备经验，专注于市场营销、采购和医疗设备技术的许可。加入MRI Interventions之前，她曾担任CSA Medical Inc.的新兴技术副总裁，在那里她曾管理公司产品的商业营销，领导公司的新兴应用在新的市场和疾病细分中的市场开发，以及开发内部和外部的产品培训计划。任职CSA Medical之前，她曾任职Boston Scientific Corporation14年以上，担任多种职务，最近担任战略和商业开发副总裁。期间，她曾开发和执行神经调节和电生理学市场的收购战略、管理和建立技术和风险资本的业务关系从而创立一个投资选择支持部门的投资组合，也曾担任科学投资的代表董事会成员/观察者，其中包括Cyberonics, Inc.、Northstar Neuroscience, Inc.、Neuropace, Inc.、Intelect Medical, Inc.、IntraPace, Inc.、Quallion LLC和公司。
- Wendelin C. Maners joined us in December 2014 as Vice President, Marketing. Ms. Maners has more than two decades of global medical device experience focused on the marketing, acquisition, and licensing of medical device technologies. Prior to joining MRI Interventions, Ms. Maners served as Vice President, Emerging Technologies with CSA Medical Inc., where she managed commercial marketing for the company’s products, led market development efforts for the company’s emerging applications in new market and disease segments and developed internal and external product training programs. Prior to her time with CSA Medical, Ms. Maners served for over 14 years in various roles at Boston Scientific Corporation, most recently as Vice President, Strategy and Business Development. During that time, she developed and executed acquisition strategies in the Neuromodulation and Electrophysiology markets, managed and built technology and venture capital business relationships to assemble a portfolio of investment options for supported divisions and served as a delegate Board member/observer for Boston Scientific investments, including Cyberonics, Inc., Northstar Neuroscience, Inc., Neuropace, Inc., Intelect Medical, Inc., IntraPace, Inc., Quallion LLC and the Company.
- Harold A. Hurwitz
Harold A. Hurwitz于2010年10月加入我司并担任首席财务官、财务总监和秘书，除此以外，从2013年2月以来担任我司首席执行官兼总裁，目前担任我司董事与提名人。在2010年3月至2010年9月期间，Hurwitz先生担任独立顾问，主要给分子诊断公司提供服务。从2008年4月到2010年2月，Hurwitz先生担任介入式脊柱股份有限公司（Interventional Spine, Inc.）的首席财务官兼副总裁，该公司是一家风险资本支持的医疗设备公司。2008年4月加入介入式脊柱股份有限公司前，Hurwitz先生担任麦克德莫特布尔公司（McDermott & Bull ）的主要咨询师，专注于医疗技术行业。Hurwitz先生从2004年12月到2005年12月担任其主要客户微型治疗股份有限公司（Micro Therapeutics, Inc.）的独立顾问，该公司是当时是上市的医疗设备公司，现在是柯惠医疗公开股份有限公司（Covidien plc. ）的子公司。他从1997年12月到2004年12月担任微型治疗股份有限公司的首席财务官。在其任职早期阶段，Hurwitz先生是库珀永道国际会计公司（Coopers & Lybrand L.L.P. ，现在称为普华永道会计师事务所（PricewaterhouseCoopers LLP））的合伙人，他在该事务所担任商业保险合伙人、奥兰治县医疗设备执业与美国证交会（SEC ）审查合伙人。他拥有广泛的财务背景，包括超过35年的公共会计与财务管理经验。此外，他在人力资源、信息技术、多元化基金募集与萨班斯奥克斯利合规（Sarbanes-Oxley compliance）方面拥有领导经验。Hurwitz先生在洛杉矶加利福尼亚大学获得经济学文学学士学位。Hurwitz先生从2013年6月一直担任我司董事。
Harold A. Hurwitz, current director and nominee, has served as our Chief Executive Officer and President since February 2013 in addition to his positions as Chief Financial Officer, Treasurer and Secretary, which he has held since joining the Company in October 2010. Between March 2010 and September 2010 Mr. Hurwitz served as an independent consultant, providing service primarily to a molecular diagnostics company. From April 2008 to February 2010 Mr. Hurwitz served as Chief Financial Officer and Vice President of Interventional Spine, Inc., a venture-backed medical device company. Prior to joining Interventional Spine in April 2008 Mr. Hurwitz served as Principal Consultant, focused on the medical technology industry, with McDermott & Bull from December 2005 to March 2008. Mr. Hurwitz served as an independent consultant from December 2004 to December 2005 with his primary client during that time being Micro Therapeutics, Inc., a then-public medical device company now part of Covidien plc. He was Chief Financial Officer of Micro Therapeutics, Inc. from December 1997 to December 2004. Earlier in his career, Mr. Hurwitz was a Partner with Coopers & Lybrand L.L.P. (now PricewaterhouseCoopers LLP), where he was a Business Assurance Partner, Team Leader of its Orange County Medical Device Practice and an SEC Review Partner. He has a broad financial background that includes more than 35 years of public accounting and financial management experience. In addition, he has leadership experience in human resources and information technology, diversified fund raising and Sarbanes-Oxley compliance. Mr. Hurwitz holds a B.A. in Economics from the University of California, Los Angeles. Mr. Hurwitz has been a director of ours since June 2013.- Harold A. Hurwitz于2010年10月加入我司并担任首席财务官、财务总监和秘书，除此以外，从2013年2月以来担任我司首席执行官兼总裁，目前担任我司董事与提名人。在2010年3月至2010年9月期间，Hurwitz先生担任独立顾问，主要给分子诊断公司提供服务。从2008年4月到2010年2月，Hurwitz先生担任介入式脊柱股份有限公司（Interventional Spine, Inc.）的首席财务官兼副总裁，该公司是一家风险资本支持的医疗设备公司。2008年4月加入介入式脊柱股份有限公司前，Hurwitz先生担任麦克德莫特布尔公司（McDermott & Bull ）的主要咨询师，专注于医疗技术行业。Hurwitz先生从2004年12月到2005年12月担任其主要客户微型治疗股份有限公司（Micro Therapeutics, Inc.）的独立顾问，该公司是当时是上市的医疗设备公司，现在是柯惠医疗公开股份有限公司（Covidien plc. ）的子公司。他从1997年12月到2004年12月担任微型治疗股份有限公司的首席财务官。在其任职早期阶段，Hurwitz先生是库珀永道国际会计公司（Coopers & Lybrand L.L.P. ，现在称为普华永道会计师事务所（PricewaterhouseCoopers LLP））的合伙人，他在该事务所担任商业保险合伙人、奥兰治县医疗设备执业与美国证交会（SEC ）审查合伙人。他拥有广泛的财务背景，包括超过35年的公共会计与财务管理经验。此外，他在人力资源、信息技术、多元化基金募集与萨班斯奥克斯利合规（Sarbanes-Oxley compliance）方面拥有领导经验。Hurwitz先生在洛杉矶加利福尼亚大学获得经济学文学学士学位。Hurwitz先生从2013年6月一直担任我司董事。
- Harold A. Hurwitz, current director and nominee, has served as our Chief Executive Officer and President since February 2013 in addition to his positions as Chief Financial Officer, Treasurer and Secretary, which he has held since joining the Company in October 2010. Between March 2010 and September 2010 Mr. Hurwitz served as an independent consultant, providing service primarily to a molecular diagnostics company. From April 2008 to February 2010 Mr. Hurwitz served as Chief Financial Officer and Vice President of Interventional Spine, Inc., a venture-backed medical device company. Prior to joining Interventional Spine in April 2008 Mr. Hurwitz served as Principal Consultant, focused on the medical technology industry, with McDermott & Bull from December 2005 to March 2008. Mr. Hurwitz served as an independent consultant from December 2004 to December 2005 with his primary client during that time being Micro Therapeutics, Inc., a then-public medical device company now part of Covidien plc. He was Chief Financial Officer of Micro Therapeutics, Inc. from December 1997 to December 2004. Earlier in his career, Mr. Hurwitz was a Partner with Coopers & Lybrand L.L.P. (now PricewaterhouseCoopers LLP), where he was a Business Assurance Partner, Team Leader of its Orange County Medical Device Practice and an SEC Review Partner. He has a broad financial background that includes more than 35 years of public accounting and financial management experience. In addition, he has leadership experience in human resources and information technology, diversified fund raising and Sarbanes-Oxley compliance. Mr. Hurwitz holds a B.A. in Economics from the University of California, Los Angeles. Mr. Hurwitz has been a director of ours since June 2013.